Category: MedTech
-
How FDA Regulations Differ for Pharma vs Medtech vs Nutraceuticals
How FDA Regulations Differ for Pharma vs Medtech vs Nutraceuticals: A Founder’s Guide For founders entering the health and wellness space, understanding FDA regulations is crucial for successful product launches and sustainable growth. The regulatory landscape varies significantly across pharmaceutical drugs, medical devices, and nutraceuticals, each with distinct pathways, requirements, and timelines. In our experience… Read more
-
QMSR vs ISO 13485: What Medtech Companies Need to Know in 2026
QMSR vs ISO 13485: What Medtech Companies Need to Know in 2026 Quality managers in the medical device industry face increasingly complex decisions about which quality management standards to implement and maintain. Two frameworks consistently emerge at the center of these discussions: the Quality Management System Regulation (QMSR) and ISO 13485. Understanding their differences, overlaps,… Read more
-
How to Determine Your Product’s Regulatory Classification
Understanding Your Product’s Place in the Regulatory Landscape When launching a medical device or health product, understanding your product classification serves as the foundation for every subsequent regulatory decision. This determination shapes your pathway to market, influences development timelines, and directly impacts your resource allocation strategy. In our year’s of experience working with medtech companies,… Read more
-
What Health & MedTech Founders Should Fix Before Starting M&A Conversations
What Founders Should Fix Before Starting M&A Conversations The M&A landscape for life science has never been more competitive. While strategic acquirers and private equity firms actively seek innovative medtech, pharma, and nutraceutical companies, they’re increasingly selective about the deals they make. In our experience working with companies through acquisition processes, the consistently same critical… Read more
-
Why Regulatory Readiness is the Most Overlooked Factor in M&A Valuations
When private equity firms and strategic acquirers evaluate life sciences companies, they typically focus on market size, intellectual property, and potential for financial performance. Yet one critical factor consistently gets relegated to the back burner: regulatory readiness. Our 25+ years of experience with medtech, pharma, and nutraceutical companies has caused us to witness how regulatory… Read more
-
QMSR Readiness for Medical Devices
Preparing for the 2026 Deadline CTI Consulting got its start in the fourth quarter of 2025, with its first assignment to perform a QMSR-focused internal audit assignment I wanted to take this opportunity to provide the insights I had as I performed this audit, so other medical device establishments are able to learn from my… Read more